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Abstract
Background: Lack of rapid and reliable susceptibility testing for second-line drugs used in the treatment of
multidrug-resistant tuberculosis (MDR-TB) may limit treatment success.
Methods: Mycobacterium tuberculosis isolates from patients referred to Kibong’oto National TB Hospital in Tanzania
for second-line TB treatment underwent confirmatory speciation and susceptibility testing. Minimum inhibitory
concentration (MIC) testing on MYCOTB Sensititre plates was performed for all drugs available in the second-line
formulary. We chose to categorize isolates as borderline susceptible if the MIC was at or one dilution lower than
the resistance breakpoint. M. tuberculosis DNA was sequenced for resistance mutations in rpoB (rifampin), inhA
(isoniazid, ethionamide), katG (isoniazid), embB (ethambutol), gyrA (fluoroquinolones), rrs (amikacin, kanamycin,
capreomycin), eis (kanamycin) and pncA (pyrazinamide).
Results: Of 22 isolates from patients referred for second-line TB treatment, 13 (59%) were MDR-TB and the
remainder had other resistance patterns. MIC testing identified 3 (14%) isolates resistant to ethionamide and
another 8 (36%) with borderline susceptibility. No isolate had ofloxacin resistance, but 10 (45%) were borderline
susceptible. Amikacin was fully susceptible in 15 (68%) compared to only 11 (50%) for kanamycin. Resistance
mutations were absent in gyrA, rrs or eis for all 13 isolates available for sequencing, but pncA mutation resultant in
amino acid change or stop codon was present in 6 (46%). Ten (77%) of MDR-TB patients had at least one
medication that could have logically been modified based on these results (median 2; maximum 4). The most
common modifications were a change from ethioniamide to para-aminosalicylic acid, and the use of higher dose
levofloxacin.
Conclusions: In Tanzania, quantitative second-line susceptibility testing could inform and alter MDR-TB
management independent of drug-resistance mutations. Further operational studies are warranted.
Keywords: Multidrug-resistant tuberculosis, Minimum inhibitory concentration, Aminoglycosides, Flouroquinolones,
Para-aminosalicylic acid, Ethionamide, rpoB, inhA, embB, pncA
Background
Management of multidrug-resistant tuberculosis (MDR-
TB) poses a major challenge, since resistance to isoniazid
and rifampin precludes the use of two key drugs in the
anti-TB regimen. Medications used in the treatment of
MDR-TB are deemed second-line because of reduced
potency, a worse side effect profile and impaired treatment
efficacy compared to medication in the standard first-
line regimen for drug-susceptible TB (isoniazid, rifampin,
ethambutol, pyrazinamide). Consequently, current World
Health Organization guidelines recommend at least
20 months of treatment duration with five drugs (a
second-line injectable agent given for at least 8 months:
capreomycin, kanamycin, or amikacin; a fluoroquinolone;
ethionamide or prothionamide; pyrazinamide; and cyclo-
serine or para-aminosalicylic acid) [1,2]. Yet the guidelines
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expose the paucity of quality evidence with which to
generate treatment recommendations, particularly with
regard to the optimal composition and duration of MDR-
TB regimens [3].
The lack of rapid and reliable susceptibility testing for
the drugs which compose the MDR-TB regimen further
limits the ability to assign the ideal combination to an in-
dividual patient. Despite individualized treatment existing
as the standard of care in areas with adequate expertise
and laboratory capacity [4], the lack of second-line suscep-
tibility testing is common in resource-limited settings
where the vast majority of MDR-TB occurs, and in such
locations empiric regimens have been advocated [1].
Empiric regimens, based on periodic surveillance of drug
resistance data, risk inclusion of medications to which
the subject’s Mycobacterium tuberculosis isolate may
be frankly resistant and discounts the pharmacokinetic
variability whereby poor circulating drug concentrations
impair killing of isolates with borderline susceptibility
and which may amplify resistance [5]. Indeed, the gold
standard of second-line susceptibility on solid agar uses
the proportion method and a single critical concentra-
tion of drug to determine qualitative susceptibility or
resistance, contrary to the quantitative readout used in the
testing of many other infectious pathogens. Furthermore,
cross-resistance is not universal among the drugs within
the flouroquinolone class or among the injectable agents
[6]. As proof of concept, meta-analysis found improved
cure rates with use of a later generation fluoroquinolone
among patients with extensively drug-resistant isolates
resistant to ofloxacin [7].
In Kibong’oto National Tuberculosis Hospital (KNTH)
in Tanzania, the country’s only MDR-TB treatment facility,
second-line drug regimens are largely empiric as sus-
ceptibility testing is available only to isoniazid, rifampin,
streptomycin and ethambutol and second-line drugs are
procured within a restricted formulary [8]. Given our local
knowledge of the gaps in second-line susceptibility testing,
we chose to perform quantitative testing by minimum
inhibitory concentration (MIC) on a series of isolates from
consecutive patients referred to KNTH. MIC testing is
now commercially available in a microplate format for
the testing of M. tuberculosis susceptibility with accuracy
of >94% for all first and many second-line drugs, and is
now used as the only phenotypic susceptibility testing in
large TB public health laboratories [9-11]. In the following
study we describe the potential application of quantitative




KNTH was a former sanatorium and is located in the
Kilimanjaro region/Siha district of northern Tanzania ap-
proximately 600 kilometers from Dar es Salaam. As the
only approved facility for use of second-line anti-TB drugs
since November 2009, KNTH received patients from the
entire country with MDR-TB, poly-resistant TB (resistant
to more than one first-line drug but retaining either isonia-
zid or rifampin susceptibility) or intolerance to first-line
drugs. MDR-TB patients were treated with a standardized
regimen during the inpatient intensive phase with one
injectable agent (kanamycin, amikacin or capreomycin
pending stock availability), a fluoroquinolone (levofloxacin
or ofloxacin), ethambutol (if susceptible), pyrazinamide,
ethionamide and cycloserine (or para-aminosalicylic acid).
Monthly sputum cultures were obtained in pulmonary
TB and monitored for conversion to negative per hospital
protocol.
Laboratory methods
All subjects were initially referred to KNTH with first-line
susceptibility testing by agar proportion at the national
reference laboratory in Dar es Salaam. Use of the rapid
molecular diagnostics, GenoType MTBDRplus (Hain Life-
science, Nehren, Germany) and GeneXpert MTB/RIF
assay (Cepheid, CA, USA) also contributed to referral in
more recent cases. In addition, KNTH retained affiliation
with the biotechnology laboratory of the Kilimanjaro Clin-
ical Research Institute (KCRI) which in addition to DNA
probe for M. tuberculosis complex (Gen-Probe, San Diego,
USA) and mycobacterial culture and conventional first-
line susceptibility testing by Bactec MGIT (BD, Franklin
Lakes, USA), performed MIC testing on MYCOTB Sensi-
titre plates (TREK Diagnostics, Cleveland, USA).
MIC testing was completed as previously described
[9,10] on a batch of consecutive M. tuberculosis isolates
and not available for therapeutic decisions. Prior to the
study MIC plates were performed in duplicate with excel-
lent agreement and rare discrepancies within one dilution.
Thus for the study, single MIC plates were read manually
by inverted mirror at 14 and 21 days by two independent
technicians. Resistance breakpoints were based on prior
published studies with MYCOTB Sensititre plates and
from critical concentrations in similar Middlebrook 7H9
liquid media [9-12], as follows: isoniazid MIC >0.25 μg/
ml (pre-filled wells of 0.06, 0.12, 0.25, 0.5, 1.0, 2.0 and
4.0 μg/ml) [9,10]; rifampin >1.0 μg/ml (pre-filled wells
of 0.12, 0.25, 0.5, 1.0, 2.0, 4.0, 8.0 and 16.0 μg/ml)
[9,10,12], rifabutin >0.5 μg/ml (pre-filled wells of 0.12,
0.25, 0.5, 1.0, 2.0, 4.0, 8.0 and 16.0 μg/ml) [9,10,13],
ethambutol >4.0 μg/ml (pre-filled wells of 0.5, 1.0, 2.0,
4.0, 8.0, 16.0 and 32.0 μg/ml) [9,10,12], streptomycin
>2.0 μg/ml (pre-filled wells of 0.25, 0.5, 1.0, 2.0, 4.0, 8.0,
16.0 and 32.0 μg/ml) [9,10], kanamycin >5.0 μg/ml (pre-
filled wells of 0.6, 1.2, 2.5, 5.0, 10.0, 20.0, and 40.0 μg/ml)
[9,10], amikacin >1.0 μg/ml (pre-filled wells of 0.12, 0.25,
0.5, 1.0, 2.0, 4.0, 8.0 and 16.0 μg/ml) [12,13], ofloxacin
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>2.0 μg/ml (pre-filled wells of 0.25, 0.5, 1.0, 2.0, 4.0,
8.0, 16.0 and 32.0 μg/ml) [9,10,12], moxifloxacin
>0.25 μg/ml (pre-filled wells of 0.06, 0.12, 0.5, 1.0, 2.0, 4.0
and 8.0 μg/ml) [12], ethionamide >5.0 μg/ml (pre-filled
wells of 0.3, 0.6, 1.2, 2.5, 5.0, 10.0, 20.0 and 40.0 μg/ml)
[9,10,12], cycloserine >32.0 μg/ml (pre-filled wells of 2.0,
4.0, 8.0, 16.0, 32.0, 64.0, 128.0 and 256.0 μg/ml) [9,10],
para-aminosalicylic acid >2.0 μg/ml (pre-filled wells of 0.5,
1.0, 2.0, 4.0, 8.0, 16.0, 32.0 and 64.0 μg/ml) [9,10,12].
While MIC ranges on solid agar of ‘moderately suscep-
tible’ or ‘moderately resistant’ have been applied for
clinical interpretation at specialized centers [14,15], we
chose to categorize MICs at or one dilution lower than
the concentration for the resistance breakpoint as bor-
derline susceptible. The term ‘intermediate’ susceptibility
was avoided given its use in other bacterial infections for
which standard breakpoints are set based on large-scale
consensus [16]. Quantitative susceptibility testing for
pyrazinamide was not available.
For additional comparison to quantitative susceptibility,
DNA was amplified and sequenced for known drug-resist-
ance determining regions of katG (high level isoniazid
resistance), inhA (ethionamide and low level isoniazid
resistance), rpoB (rifampin), embB (ethambutol), gyrA
(fluoroquinolones), rrs (amikacin, kanamycin, capreomycin),
and eis (kanamycin) using methods described from the US
Centers for Disease Control [17]. For pncA (pyrazina-
mide), the entire open reading frame and upstream
promoter region were amplified. Comparison was made
with published sequences for M. tuberculosis H37Rv
using GeneDoc 2.7.0.
Statistical analysis
Basic demographic data were abstracted from patient
charts along with clinical information including HIV
status, prior TB treatment episodes, duration of sputum
culture conversion in months (if applicable) and drugs
in the treatment regimen during the inpatient intensive
phase. Data were entered into Microsoft Excel (Version
14.1.3) and analyzed using SPSS (Version 19).
The proportion of susceptible, borderline susceptible
and resistant was reported as simple frequencies for each
drug included on the MYCOTB Sensitire plate. Medians
and range were used to describe the number of drugs
within the study population for which a medication modi-
fication was probable. A probable medication modification
was defined as a borderline susceptible or resistant drug
in the patient’s regimen for which there was an alternative
susceptible drug available, or for a borderline susceptible
isolate, a dose increase was possible [4]. Medication modi-
fication was restricted to second-line drugs for which
Bactec MGIT susceptibility was not available. The number
of drugs for which a medication modification was prob-
able and the duration of sputum culture conversion were
compared by chi-square with p-value of less than 0.05
considered significant.
Ethical approval was obtained from the institutional
review boards of the Kilimanjaro Christian Medical Uni-
versity and the University of Virginia, and KNTH hospital
management.
Results
Isolates from 22 patients were available for analysis.
Sixteen patients (73%) were male with a mean age of
39 years ± 14. Five (23%) were HIV infected with a mean
CD4 count of 342 cells/μl (minimum 242- maximum
443). All patients had at least one prior episode of TB
and 9 (41%) had three or more prior episodes. All patients
had pulmonary TB and the median duration of culture
conversion was 2 months (IQR 1–3). Time to culture con-
version did not vary by HIV status.
All 22 isolates were confirmed as M. tuberculosis
complex by probe. Thirteen (59%) were MDR following
repeat susceptibility testing in Bactec MGIT, while the
remainder had other resistance patterns to the first-line
drugs. For the first-line drugs, MIC testing did not differ
in agreement between two technicians and was compared
to the conventional Bactec MGIT result (Table 1).
For isoniazid, only one isolate was discrepant with a
MIC > 4.0 μg/ml but susceptible in Bactec MGIT.
DNA was available for sequencing and found to be
wildtype for both inhA and katG. Similarly for rifampin,
20 (91%) correlated, but one isolate, read as susceptible
for rifampin by Bactec MGIT, had a MIC indicative of
resistance (>16 μg/ml). rpoB was wild-type by both se-
quencing and GeneXpert MTB/RIF assay, supportive of
the Bactec MGIT result. Interestingly, the one isolate
Table 1 Minimum inhibitory concentration (MIC) for
first-line drugs compared to Bactec MGIT results
(N = 22 isolates)
Drug and MIC result MGIT susceptible MGIT resistant Accuracy
Isoniazid 95.5%
MIC Susceptible 4 0
MIC Resistant 1 17a
Rifampin 90.9%
MIC Susceptible 8 1b
MIC Resistant 1 12c
Streptomycin 90.9%
MIC Susceptible 13 0
MIC Resistant 2 7
Ethambutol 59.1%
MIC Susceptible 11 1e
MIC Resistant 7f 2
aAll with isoniazid MIC ≥ 4 μg/ml. bRifampin MIC of 1 μg/ml. cAll with rifampin
MIC >16 μg/ml. eEthambutol MIC of 4 μg/ml. fFive (71%) with ethambutol MIC
of 8 μg/ml.
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susceptible by MIC testing that was resistant to rifampin
in Bactec MGIT had a MIC of 1.0 μg/ml at the resist-
ance breakpoint. Accuracy of ethambutol was only 59%,
due largely to Bactec MGIT susceptible isolates with a
MIC one dilution above the resistance breakpoint.
For the second-line drugs tested, a range of MICs were
observed (Table 2). For example, while only 1 isolate (5%)
was resistant to kanamycin, 10 (45%) were of borderline
susceptibility. Similarly, no isolates were ofloxacin re-
sistant, but 10 (45%) were of borderline susceptibility. In
contrast, 3 (14%) of isolates were ethionamide resistant
and another 8 (36%) were of borderline susceptibility,
while para-aminosalicylic acid was fully susceptible in
15 (68%) of cases.
DNA was extracted and amplified from 13 isolates
with MIC testing, including 8 (62%) with MDR-TB. For
isoniazid, inhA was wildtype in all isolates, and katG
mutated in all resistant isolates when comparing to Bactec
MGIT susceptibility (Table 3). Complete agreement was
also found for rpoB mutation and rifampin resistance
when comparing to the Bactec MGIT result. Yet for
ethambutol, only one isolate was resistant in Bactec
MGIT but lacked embB mutation, whereas in the 12
remaining isolates susceptible to ethambutol, 6 (50%)
had embB mutation. In contrast, by MIC testing for
ethambutol, 3 isolates were found resistant and 2 (67%)
had an embB mutation while 7 isolates were of borderline
susceptibility and 3 (43%) had embB mutation. No isolate
had rrs or eis mutation despite one isolate with MICs
to kanamycin of >40 μg/ml and amikacin of 16 μg/ml,
both in the resistant range. Eleven (85%) had mutation
in gyrA but at a site known to be phenotypically silent
and not conferring of resistance (Ser95Thr) [18] and cor-
respondingly none of the 13 isolates had an ofloxacin
MIC >2.0 μg/ml. However, 10 (77%) had point mutations
in pncA, including 6 (47%) conferring amino acid changes
or stop codons.
The pattern of second-line non-susceptibility was dif-
ficult to predict and led to a highly variable number
and class of medications where modification was probable.
Of the MDR-TB patients, 10 (77%) had at least one medi-
cation with probable modification (median 2, maximum
4) (Table 4). The most common medication modification
was changing ethionamide to para-aminosalicylic acid,
which was probable in 7 (54%). Additionally, there were 3
patients (23%) on kanamycin with borderline or resistant
MICs while amikacin retained full susceptibility. Among
the non-MDR patients, all 9 (100%) had at least one medi-
cation with probable modification.
Comparison of culture conversion was restricted to
MDR-TB patients only given the more rapid culture
conversion expected for patients continued on either
isoniazid or rifampin. Among the MDR-TB patients, there
were 6 (46%) that converted their sputum culture to nega-
tive in ≤ 2 months while the remainder required 3 months
or more. In the early culture converters 4 (67%) had ≤1
medication with probable modification compared to 3
(43%) of late culture converters (p = 0.59).
Table 2 Minimum inhibitory concentration (MIC) for second-line drugs (N = 22 isolates)
Drug Susceptible (% N) Borderline susceptible (% N) Resistant (% N)
[MIC range] [MIC range] [MIC range]
Kanamycin 11 (50) 10 (45) 1 (5)
[≤0.6-1.2 μg/ml] [2.5-5.0 μg/ml] [>40.0 μg/ml]
Amikacin 15 (68) 6 (27) 1 (5)
[≤0.12-0.25 μg/ml] [≤0.5-1.0 μg/ml] [16 μg/ml]
Ofloxacina 12 (55) 10 (45) 0
[≤0.25-0.5 μg/ml] [1.0-2.0 μg/ml] N/A
Moxifloxacin 11 (50) 10 (45) 1 (5)
[≤0.6 μg/ml] [≤0.12-0.25 μg/ml] [0.5 μg/ml]
Ethionamide 11 (50) 8 (36) 3 (14)
[0.5-1.2 μg/ml] [2.5-5.0 μg/ml] [10.0-40.0 μg/ml]
Cycloserine 17 (77) 5 (23) 0
[1.2-8.0 μg/ml] [16.0-32.0 μg/ml] N/A
PAS 15 (68) 2 (9) 5 (23)
[≤0.5 μg/ml] [1.0 μg/ml] [8.0- >64.0 μg/ml]
Rifabutin 9 (41) 0 13 (59)
[≤0.12 μg/ml] N/A [1.0- >16.0 μg/ml]
PAS para-aminosalicylic acid. aPatients received ofloxacin or levofloxacin. Moxifloxacin and rifabutin were not available on formularly.
Mpagama et al. BMC Infectious Diseases 2013, 13:432 Page 4 of 8
http://www.biomedcentral.com/1471-2334/13/432
Discussion
In this study of patients referred to a TB hospital in
Tanzania for second-line therapy, the majority had one
or more medication that could have rationally been modi-
fied with the application of quantitative susceptibility.
The frequency of borderline susceptible or resistant medi-
cations are of particular importance given that the total
number of active medications in a MDR-TB regimen is
one of the few factors predictive of treatment success
[19]. We harbor further concern for later outcomes
such as relapse given that pncA mutation was common
and the suspected pyrazinamide resistance may negate
another key drug in the empiric second-line regimen.
While patients with a longer duration of sputum culture
conversion had more medications with probable modi-
fication this association was not statistically significant
given the limited number of subjects with MDR-TB for
comparison. Importantly, patterns of non-susceptibility
were difficult to predict, further emphasizing the potential
utility of individualized testing.
Ethionamide was resistant or borderline susceptible in
half of all isolates. Bactericidal at high enough concen-
trations, ethionamide remains the favored drug among
the group IV agents of cycloserine, terizidone and para-
aminosalicylic acid, and has been associated with im-
proved cure rates for MDR-TB [2]. Yet ethionamide is
a structural anologue of isoniazid and has shown cross
resistance [20-22], particularly when there is mutation
in the inhA promoter region. Our analysis was limited
to only one isolate with ethionamide resistance by MIC
where DNA sequencing was performed and inhA was
Table 3 Molecular targets of resistance distributed by Bactec MGIT result or category of minimum inhibitory
concentration (MIC) (N = 13 isolates)
Drug; gene MGIT MGIT MIC MIC MIC
Susceptible Resistant Susceptible Borderline
Resistantsusceptible
Rifampin; rpoB
wildtype 5 0 4 N/A 1
mutation 0 8 0 N/A 8
Isoniazid; inhA or katG
wildtype 4 0 2 N/A 1
mutation 0 9 0 N/A 10
Ethambutol; embB
wildtype 6 1 2 4 1
mutation 6 0 1 3 2
Ofloxacin; gyrA
wildtype/silent mutation N/A N/A 6 7 N/A
mutation N/A N/A 0 0 N/A
Amikacin; rrs or eis
wildtype N/A N/A 8 4 1
mutation N/A N/A 0 0 0
Ethionamide; inhA
wildtype N/A N/A 5 7 1
mutation N/A N/A 0 0 0
embB mutation included: Glu378Ala in 2 isolates; Met306Val, Met306Ile, Gly406Asp, Gly406Cys, Tyr319Cys in single isolates. Pyrazinamide susceptibility was not
performed but pncA mutations included: Val128Gly in 2 isolates; Glu111stop, Asp49Gly, Ser179Ile, and Val169Ala in single isolates. Val128Gly and Val169Ala have
not previously been reported. Five isolates (63%) resistant to both isoniazid and rifampin had pncA mutation.
Table 4 Distribution of probable medication changes for
MDR-TB patients (N = 13)
Modification Frequency (% N)
Ethionamide change to para-aminosalicylic acid 7 (54)
Ofloxacin or levofloxacin change to
high-dose levofloxacin
6 (46)
Kanamycin change to amikacin 3 (23)
Amikacin or kanamycin empiric change
to capreomycina
3 (23)
Amikacin change to kanamycin 1 (8)
aTerm empiric change used because amikacin and kanamycin were both
resistant or of borderline susceptibility, and use of capreomycin has been
empirically advocated in this setting [1], but capreomycin testing was not
performed in this study. In 2 subjects with borderline susceptible cycloserine
another class switch was not available. They were each receiving cycloserine
at 500 mg daily and while escalation of dose to 750 mg daily is possible (split
in two doses in morning and before bed), such increase may have prohibitive
neuropsychiatric toxicity.
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not mutated. Furthermore, the achievable peak serum
concentration of ethionamide (1–5 μg/ml) are very near
the critical concentration used to define in vitro resistance
and thus isolates of borderline susceptibility may be par-
ticularly at risk of inadequate killing in a patient with
suboptimal serum drug concentrations [23]. As cyclo-
serine was used in conjunction with ethionamide in the
majority of the cases studied, the possible change from
ethionamide to para-aminosalicylic acid represented the
most likely clinical action among MDR-TB patients.
Fortunately frank resistance to ofloxacin was absent, but
there were many patients with isolates of borderline
susceptibility that may have benefited from higher dose
levofloxacin or an alternative later generation flouroqui-
nolone [4,24,25]. Reports continue to suggest that later
generation fluoroquinolones retain susceptibility against
ofloxacin non-susceptible strains [24] and for levofloxacin,
the best pharmacokinetic properties appear to be at
dose of 1000 mg daily [25,26]. All patients prescribed
levofloxacin at KNTH were given 750 mg daily and
thus empiric dosing of 1000 mg, except at the lowest
patient weight range, is worth consideration (Figure 1).
Such dosing may prove particularly relevant for borderline
susceptible isolates given recent pharmacokinetic studies
suggesting that in patients with MDR-TB and an ofloxacin
MIC of 2.0 μg/ml treated with standard doses of ofloxacin,
none achieved the target serum area under the time
curve (AUC)/MIC [27]. Yet, while the resistance break-
point for ofloxacin of >2.0 μg/ml appears consistent across
platforms of solid and liquid media [12], moxifloxacin
has varied from 0.5 μg/ml for the agar proportion
method on Middlebrook 7H10 and 7H11, and 0.25 μg/ml
in Bactec MGIT which employs an enriched 7H9 liquid
media similar to the MYCOTB Sensititre plate. However,
recent studies of MYCOTB Sensititre in comparison
to agar proportion have suggested a moxifloxacin MIC
of >2 μg/ml as resistant [9,10] but there were few isolates
resistant on agar and the number with moxifloxacin MIC
in the range of 0.25-2.0 μg/ml was not explicitly stated.
Of note, all 22 isolates in our study had a moxifloxacin
MIC of ≤0.5 μg/ml and in the isolates sequenced, none
had a gyrA mutation. Such discrepancy highlights the
importance of acquiring further quantitative susceptibility
in a standardized platform on isolates with well character-
ized epidemiology.
The application of quantitative susceptibility for optim-
ization of drugs within the MDR-TB regimen may be
all the more important given the challenges of routine
pyrazinamide susceptibility testing. More than 60% of
the MDR isolates available for sequencing in this study
had a mutation resultant in amino acid change or a stop
codon in the pncA gene, including two mutations in three
isolates not previously reported. pncA encodes the pyrazi-
namidase responsible for converting pyrazinamide to the
active form of pyrazinoic acid and mutations in the gene
perform reasonably well for prediction of resistance with
sensitivity of 85% and specificity of 86% in a large series
of isolates from the US Centers for Disease Control
[17]. However genotyping for pncA requires substantial
amplification and sequencing across the entire 558 base
pair gene [28]. Additionally, conventional methods are
technically demanding and poorly reproducible given the
requirement for acidified media and attendant growth
constraints. Thus, pyrazinamide has been excluded from
commercial MIC plates and ongoing research will be
required to determine if mutation in any specific region of
Figure 1 Potential application of quantitative second-line drug-susceptibility testing for treatment optimization at a multidrug-resistant
referral hospital. Legend. Dotted line represents modification of empiric regimen based on quantitative susceptibility.
Mpagama et al. BMC Infectious Diseases 2013, 13:432 Page 6 of 8
http://www.biomedcentral.com/1471-2334/13/432
the pncA gene will be associated with a more substantial
quantitative change in susceptibility than other regions
of the gene.
For the remainder of the drugs beside pyrazinamide
that make up a typical MDR-TB regimen, we favor the
relative ease of the quantitative MIC plate in set up,
reading of results, and the fact that it contains quantitative
information that is additive to molecular testing alone.
As a screening tool however prior to referral for MDR-TB
treatment, our results suggest that in Tanzania inhA and
katG genotypic methods could be utilized. Further study
is required to determine if inhA may be used to determine
the empiric choice of ethionamide or para-aminosalicylic
acid pending MIC testing (Figure 1). In contrast, given the
low proportion of isolates with injectable agent resistance
and the lack of rrs or eis mutation noted in the isolates
available for sequencing, as well as the absence of gyrA
mutation in the isolates of borderline susceptibility to
ofloxacin, new line-probe assays for these targets may
be of less value [29]. Instead, MIC testing would allow
for selection within the class of aminoglycosides and
support the use of higher dose levofloxacin (Figure 1).
Of note, there was a seemingly better correlation with
embB mutation and the MIC plate for ethambutol than
to the Bactec MGIT result. This may explain the poor
specificity of embB observed in field studies using MGIT
as the comparator [6]. While such discrepancies can
occur in a qualitative susceptibility platform for any
isolate with a MIC near the critical concentration, this
appears particularly common for ethambutol when using
MGIT as the comparator, and laboratories such as the
Florida Bureau of Public Health that use the Sensitire
MYCOTB plate exclusively for phenotypic susceptibility
testing, now report an intermediate range for ethambutol,
streptomycin and isoniazid [11]. Furthermore, all embB
mutations found in this cohort have been associated
with in vitro resistance in other studies, but commercial
line-probe assays have focused on a single codon (306)
of the gene [17,29], further dampening enthusiasm for
their utility in our setting.
In summary, we believe quantitative susceptibility me-
thods would prove a worthwhile investment similar to
other MDR-TB programs where individualized manage-
ment based on second-line drug-susceptibility has been
modeled as cost-effective [30,31]. For example, despite the
subsidized price for second-line medications in Tanzania
procured through the WHO Green Light Committee initia-
tive, a switch from kanamycin ($0.53 USD per typical injec-
tion) to amikacin ($0.15 USD) [32], as was the potential for
23% of the MDR patients studied based on MIC testing,
would pay for the cost of the MIC plate (~$40 each) during
the 8 months or more of drug administration. While a
major advantage of the commercial plate was the lyophi-
lized drug of each concentration in the prefilled wells,
and the ease of implementation into a laboratory already
performing TB culture, similar in-house platforms could
be developed that may ultimately defray cost.
There are several limitations to our analysis that warrant
consideration. The findings were restricted to a small
number of clinical isolates and cannot necessarily be
generalized to other settings. Additionally, the critical
concentrations used to define qualitative resistance for
second-line medications remain a subject of debate, are
influenced by the platform of testing, and ultimately re-
quire rigorous clinical follow-up among large numbers
of patients [33]. As such our categorization of border-
line susceptibility may be imprecise, particularly for
medications such as cycloserine that are not entirely
concentration dependent in their activity. Also, our only
marker of treatment success was culture conversion,
which is also dependent upon numerous host factors.
We were unable to determine if patients with border-
line susceptible or resistant isolates, particularly those
of a certain class of drug, had a higher likelihood of worse
late outcomes such as reversion of culture positivity dur-
ing the outpatient continuation phase, or relapse following
treatment completion. Despite these limitations we be-
lieve quantitative susceptibility testing holds promise
for second-line regimen optimization in Tanzania and
further studies to explore the use of such testing should
be pursued.
Conclusions
In Tanzania, quantitative second-line susceptibility testing
could inform and alter MDR-TB management independ-
ent of drug-resistance mutations. Further operational stud-
ies are warranted with a standardized platform for MIC
testing and informed by resistance breakpoints from
isolates with well characterized epidemiology and clin-
ical outcome.
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